A clinical trial of trimebutine (Mebutin) in spastic colon.

Abstract

Twenty adult Indian patients suffering from the spastic form of irritable colon, i.e. abdominal pain and constipation, were given trimebutine (Mebutin), 2-phenyl, 2-dimethylamino-n-butyl 3, 4, 5-trimethoxybenzoate. Patients were given treatment with 200 mg trimebutine three times daily, or placebo for 4 weeks, and then crossed over. In addition, stool transit times were assessed by the single stool transit time (SST) method of Cummings. Results showed a statistical improvement in abdominal pain and constipation with both trimebutine and placebo after 4 weeks, but only with trimebutine after 8 weeks. Single stool transit time was significantly reduced after trimebutine.

• Authors: M G Moshal, M Herron
• Journal: The Journal of international medical research (J Int Med Res) Vol. 7 Issue 3 Pg. 231-4 ( 1979) ISSN: 0300-0605 [Print] England
• PMID: 456734 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Benzoates
• Placebos
• Trimebutine

Topics

• Adult
• Benzoates (therapeutic use)
• Colonic Diseases, Functional (drug therapy)
• Double-Blind Method
• Female
• Gastrointestinal Motility (drug effects)
• Humans
• Male
• Placebos
• Trimebutine (therapeutic use)